Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G
Edgardo D. Carosella, Guillaume Ploussard, Joël LeMaoult, et al.
European Urology (2015) Vol. 68, Iss. 2, pp. 267-279
Closed Access | Times Cited: 213

Showing 1-25 of 213 citing articles:

Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology
Philipp Nuhn, Johann S. de Bono, Karim Fizazi, et al.
European Urology (2018) Vol. 75, Iss. 1, pp. 88-99
Closed Access | Times Cited: 396
Mechanisms of BCG immunotherapy and its outlook for bladder cancer
C. Pettenati, Molly A. Ingersoll
Nature Reviews Urology (2018) Vol. 15, Iss. 10, pp. 615-625
Closed Access | Times Cited: 382
HLA-G
Edgardo D. Carosella, Nathalie Rouas‐Freiss, Diana Tronik‐Le Roux, et al.
Advances in immunology (2015), pp. 33-144
Closed Access | Times Cited: 341
Microsatellite Instability: A Predictive Biomarker for Cancer Immunotherapy
Liisa Chang, Minna Chang, Hanna M. Chang, et al.
Applied immunohistochemistry & molecular morphology (2017) Vol. 26, Iss. 2, pp. e15-e21
Closed Access | Times Cited: 311
Molecular Drivers of the Non–T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer
Randy F. Sweis, Stefani Spranger, Riyue Bao, et al.
Cancer Immunology Research (2016) Vol. 4, Iss. 7, pp. 563-568
Open Access | Times Cited: 310
Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix
A. Marijne Heeren, Simone Punt, Maaike Bleeker, et al.
Modern Pathology (2016) Vol. 29, Iss. 7, pp. 753-763
Open Access | Times Cited: 277
CXCL1-Mediated Interaction of Cancer Cells with Tumor-Associated Macrophages and Cancer-Associated Fibroblasts Promotes Tumor Progression in Human Bladder Cancer
Makito Miyake, Shunta Hori, Yosuke Morizawa, et al.
Neoplasia (2016) Vol. 18, Iss. 10, pp. 636-646
Open Access | Times Cited: 197
Activation of the PD-1/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis
Madison Black, Ivraym B. Barsoum, Peter Truesdell, et al.
Oncotarget (2016) Vol. 7, Iss. 9, pp. 10557-10567
Open Access | Times Cited: 169
Programmed death receptor (PD-)1/PD-ligand (L)1 in urological cancers : the “all-around warrior” in immunotherapy
Qiang Liu, Yujing Guan, Shenglong Li
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 15
Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches
Aaron M. Udager, Ting‐yu Liu, Stephanie L. Skala, et al.
Annals of Oncology (2016) Vol. 27, Iss. 9, pp. 1706-1712
Open Access | Times Cited: 146
PD-1 and cancer: molecular mechanisms and polymorphisms
Arash Salmaninejad, Vahid Khoramshahi, Alireza Azani, et al.
Immunogenetics (2017) Vol. 70, Iss. 2, pp. 73-86
Closed Access | Times Cited: 139
Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy
Roberta Mazzone, Clemens Zwergel, Antonello Mai, et al.
Clinical Epigenetics (2017) Vol. 9, Iss. 1
Open Access | Times Cited: 133
Heterogeneity of HLA-G Expression in Cancers: Facing the Challenges
Aifen Lin, Wei‐Hua Yan
Frontiers in Immunology (2018) Vol. 9
Open Access | Times Cited: 121
Systematic Review of Immune Checkpoint Inhibition in Urological Cancers
Maud Rijnders, Ronald de Wit, Joost L. Boormans, et al.
European Urology (2017) Vol. 72, Iss. 3, pp. 411-423
Closed Access | Times Cited: 105
Immune checkpoint blockade opens a new way to cancer immunotherapy
Sanam Sadreddini, Behzad Baradaran, Ali Aghebati‐Maleki, et al.
Journal of Cellular Physiology (2018) Vol. 234, Iss. 6, pp. 8541-8549
Closed Access | Times Cited: 104
Recent trends in the management of advanced prostate cancer
Chad R. Ritch, Michael S. Cookson
F1000Research (2018) Vol. 7, pp. 1513-1513
Open Access | Times Cited: 98
The Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology Advancements
Pierre-Olivier Gaudreau, John Stagg, Denis Soulières, et al.
Biomarkers in Cancer (2016) Vol. 8s2, pp. BIC.S31802-BIC.S31802
Open Access | Times Cited: 91
Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients
Kimberly R. Kalli, Matthew S. Block, Pashtoon Murtaza Kasi, et al.
Clinical Cancer Research (2018) Vol. 24, Iss. 13, pp. 3014-3025
Open Access | Times Cited: 87
Copper-Doped Nanoscale Covalent Organic Polymer for Augmented Photo/Chemodynamic Synergistic Therapy and Immunotherapy
Chunling Hu, Lihan Cai, Sainan Liu, et al.
Bioconjugate Chemistry (2020) Vol. 31, Iss. 6, pp. 1661-1670
Closed Access | Times Cited: 73
Mechanisms of drug resistance to immune checkpoint inhibitors in non-small cell lung cancer
Kexun Zhou, Shuo Li, Yi Zhao, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 24
Mini-Review: Current Bladder Cancer Treatment—The Need for Improvement
Emily Gill, Claire M. Perks
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 3, pp. 1557-1557
Open Access | Times Cited: 10
Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma
Chunyan Hao, Jinhui Tian, Huiling Liu, et al.
Medicine (2017) Vol. 96, Iss. 26, pp. e7325-e7325
Open Access | Times Cited: 85
Incidence of Immune-Related Adverse Events with Program Death Receptor-1- and Program Death Receptor-1 Ligand-Directed Therapies in Genitourinary Cancers
Benjamin L. Maughan, Erin Bailey, David Gill, et al.
Frontiers in Oncology (2017) Vol. 7
Open Access | Times Cited: 83
Expression of PD-L1 in Hormone-naïve and Treated Prostate Cancer Patients Receiving Neoadjuvant Abiraterone Acetate plus Prednisone and Leuprolide
Carla Calagua, Joshua W. Russo, Yue Sun, et al.
Clinical Cancer Research (2017) Vol. 23, Iss. 22, pp. 6812-6822
Open Access | Times Cited: 79
Immune microenvironment and evasion mechanisms in adenoid cystic carcinomas of salivary glands
Carla Mosconi, José Alcides Almeida de Arruda, ANA CAROLINE RODRIGUES DE FARIAS, et al.
Oral Oncology (2018) Vol. 88, pp. 95-101
Closed Access | Times Cited: 78
Page 1 - Next Page

Scroll to top